New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTCVE, VPHM, DUK, FTI, RPM, GMCR, SYMC, PDH, CS, BSX, MLNX, CLF, RAS, MXIM, CELGOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 22, 2015
16:05 EDTMXIMMaxim Integrated sees Q3 EPS ex-items 32c-38c, consensus 33c
Subscribe for More Information
16:03 EDTMXIMMaxim Integrated reports Q2 EPS ex-items 33c, consensus 30c
Subscribe for More Information
15:32 EDTMXIMNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Starbucks (SBUX), consensus 80c; Capital One (COF), consensus $1.74; Intuitive Surgical (ISRG), consensus $4.38; KLA-Tencor (KLAC), consensus 52c; Altera (ALTR), consensus 35c; E-Trade (ETFC), consensus 23c... ResMed (RMD), consensus 62c; Maxim Integrated Products (MXIM), consensus 30c; Maxim Integrated Products (MSCC), consensus 65c; Hexcel (HXL), consensus 54c; Polycom (PLCM), consensus 23c; Skyworks (SWKS), consensus $1.19; Curtiss-Wright (CW), consensus $1.00.
15:04 EDTMXIMMaxim Integrated technical remarks ahead of results
Subscribe for More Information
10:03 EDTGMCR, CVEOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTDUKDuke Energy to build 13-megawatt solar facility at Camp Lejeune
Subscribe for More Information
09:39 EDTGMCRKeurig Green Mountain downgraded to Neutral at Consumer Edge Research
07:40 EDTCVECenovus Energy downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
07:31 EDTBSXBoston Scientific damages in case likely to be manageable, says Wells Fargo
Subscribe for More Information
05:47 EDTBSXStocks with implied volatility movement; BSX T
Stocks with implied volatility movement; Boston Scientific (BSX) 49, AT&T (T) 20 according to iVolatility.
January 21, 2015
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
January 20, 2015
14:06 EDTCLFCitizens, Keysight identified as long positions by Einhorn
Subscribe for More Information
13:24 EDTCLFGreenlight has new long positions in Citizens, Time Warner, Bloomberg says
Subscribe for More Information
08:41 EDTCSCredit Suisse's capital ratios not changed by unstable Swiss franc, Reuters says
Subscribe for More Information
06:39 EDTCSCredit Suisse will charge certain clients for franc accounts, Reuters says
On January 22, Credit Suisse will begin charging some large corporate clients for franc accounts in order to introduce negative interest rates, reports Reuters, citing Credit Suisse spokeswoman Daniela Haesler. Reference Link
January 19, 2015
10:59 EDTDUKFERC requests additional information to process Dynegy acquisitions applications
Dynegy (DYN) announced that the Federal Energy Regulatory Commission, FERC, issued a letter requesting additional information to process the applications filed with FERC on September 11 for approval of Dynegy’s acquisition of Duke Energy Midwest Generation (DUK) assets and retail business and EquiPower Resources and Brayton Point Holdings assets. The company plans to respond fully within the 30-day period however, due to this request for additional information, we do not expect the transactions to close by the end of the first quarter 2015. Dynegy, Duke and Energy Capital Partners remain committed to closing the transactions as quickly as possible. The only regulatory approval remaining is from FERC.
January 16, 2015
16:29 EDTCSOn The Fly: Closing Wrap
Subscribe for More Information
11:36 EDTCLFCliffs Natural volatility elevated on wide price movement
Cliffs Natural January weekly call option implied volatility is at 96. January is at 98, March is at 88, compared to its 26-week average of 79 according to Track Data, suggesting large price movement.
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
08:51 EDTMLNXMellanox has positive outlook from Intel results, says Stifel
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use